Detalles de la búsqueda
1.
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
Blood
; 130(19): 2084-2091, 2017 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28835440
2.
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Cancer
; 124(6): 1160-1168, 2018 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266206
3.
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Blood
; 119(9): 1981-7, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22228624
4.
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Blood
; 117(6): 1822-7, 2011 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21030554
5.
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Blood
; 118(17): 4541-6; quiz 4759, 2011 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21803854
6.
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Blood
; 118(16): 4353-8, 2011 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21846902
7.
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Lancet Oncol
; 13(4): 403-11, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22357140
8.
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Blood
; 114(11): 2232-5, 2009 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19531657
9.
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Blood
; 113(10): 2154-60, 2009 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19060245
10.
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood
; 113(21): 5058-63, 2009 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-19282457
11.
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.
Invest New Drugs
; 29(2): 323-31, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20091088
12.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Mol Cancer Ther
; 7(1): 48-58, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18202009
13.
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Int J Hematol
; 109(5): 545-552, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30830579
14.
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
J Hematol Oncol
; 12(1): 1, 2019 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30606227
15.
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Int J Hematol
; 107(6): 689-695, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29464484
16.
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Blood
; 115(26): 5428-9, 2010 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20595523
17.
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Clin Lymphoma Myeloma
; 7 Suppl 2: S51-7, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17382013
18.
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
J Clin Oncol
; 21(6): 1167-73, 2003 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12637486
19.
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leuk Lymphoma
; 46(7): 993-7, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16019549
20.
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clin Cancer Res
; 9(1): 160-6, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12538464